前收市價 | 2.5800 |
開市 | 2.5800 |
買盤 | 2.4600 x 100 |
賣出價 | 2.5200 x 200 |
今日波幅 | 2.4200 - 2.5900 |
52 週波幅 | 0.3330 - 20.9000 |
成交量 | |
平均成交量 | 2,627,211 |
市值 | 246.434M |
Beta 值 (5 年,每月) | 0.66 |
市盈率 (最近 12 個月) | 無 |
每股盈利 (最近 12 個月) | -2.9200 |
業績公佈日 | 2024年5月06日 - 2024年5月10日 |
遠期股息及收益率 | 無 (無) |
除息日 | 無 |
1 年預測目標價 | 1.25 |
Stoke Therapeutics (STOK) gains on meaningful clinical data from STK-001 studies for the treatment of Dravet syndrome.
Stocks are at the mercy of many factors, and often, prices are just a poor earnings report or a negative headline away from a significant drop. There are times when nobody has any way of preparing. In many instances, however, early signs of trouble creep in. Sensible investors can identify potential issues from declining financial reports, brewing service problems, poorly managed spending, or questionable business decisions. Unfortunately, these three companies all show these signs, which may me
Crinetics (CRNX) stock rises after achieving goals in the second late-stage study evaluating paltusotine in patients with acromegaly who are treatment-naive or not currently receiving medical therapy.